- Home
- RXST
RXST
RxSight Inc.
as 12-20-2024 4:00pm EST
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | ALISO VIEJO |
| Market Cap: | 2.0B | IPO Year: | 2021 |
| Target Price: | $59.00 | AVG Volume (30 days): | 840.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $33.03 - $66.54 | Next Earning Date: | 11-07-2024 |
| Revenue: | $128,293,000 | Revenue Growth: | 67.52% |
| Revenue Growth (this year): | 60.3% | Revenue Growth (next year): | 34.32% |
Stock Insider Trading Activity of RxSight Inc. (RXST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Goldshleger Ilya | RXST | See remarks | Nov 29 '24 | Sell | $46.08 | 3,105 | $143,078.40 | 42,246 | |
| Maniar Shweta | RXST | Director | Nov 26 '24 | Sell | $45.88 | 3,782 | $173,518.16 | 10,902 | |
| Goldshleger Ilya | RXST | See remarks | Nov 22 '24 | Sell | $45.44 | 6,200 | $281,728.00 | 42,246 | |
| Goldshleger Ilya | RXST | See remarks | Nov 15 '24 | Sell | $45.36 | 7,975 | $363,752.31 | 42,246 | |
| Corley Jesse Anderson | RXST | Director | Nov 12 '24 | Buy | $44.96 | 22,476 | $1,014,570.10 | 474,141 | |
| Goldshleger Ilya | RXST | See remarks | Nov 12 '24 | Sell | $46.13 | 1,330 | $61,356.23 | 42,246 | |
| Goldshleger Ilya | RXST | See remarks | Nov 7 '24 | Sell | $55.25 | 3,100 | $170,494.64 | 42,246 | |
| Goldshleger Ilya | RXST | See remarks | Nov 4 '24 | Sell | $51.36 | 3,100 | $158,247.08 | 42,246 | |
| Goldshleger Ilya | RXST | See remarks | Oct 30 '24 | Sell | $51.91 | 3,105 | $161,170.92 | 42,246 | |
| Goldshleger Ilya | RXST | See remarks | Oct 25 '24 | Sell | $50.22 | 6,200 | $311,353.77 | 42,246 |
Latest RxSight Inc. News
RXST Breaking Stock News: Dive into RXST Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
RxSight Shares Fall After Stifel Downgrade
Insider Monkey
2 days ago
Do You Believe in the Long-Term Growth Potential of RxSight (RXST)?
MT Newswires
2 days ago
Stifel Downgrades RxSight to Hold From Buy, Adjusts Price Target to $40 From $65
Simply Wall St.
2 days ago
Positive week for RxSight, Inc. (NASDAQ:RXST) institutional investors who lost 1.6% over the past year
MT Newswires
11 days ago
Wells Fargo Downgrades RxSight to Equal Weight From Overweight, $56 Price Target
MT Newswires
16 days ago
UBS Initiates RxSight at Buy With $52 Price Target
Zacks
a month ago
RxSight (RXST) Upgraded to Buy: Here's What You Should Know
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 11/15/2024
Compare RXST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RXST RxSight Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.